levofloxacin has been researched along with linezolid in 118 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (linezolid) | Trials (linezolid) | Recent Studies (post-2010) (linezolid) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 3,916 | 222 | 2,188 |
| Protein | Taxonomy | levofloxacin (IC50) | linezolid (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 8.19 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 2.1 | |
| Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial | Homo sapiens (human) | 8.19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 55 (46.61) | 29.6817 |
| 2010's | 47 (39.83) | 24.3611 |
| 2020's | 16 (13.56) | 2.80 |
| Authors | Studies |
|---|---|
| Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Inagaki, H; Takahashi, H; Takemura, M | 1 |
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Abbanat, D; Bush, K; Flamm, RK; Foleno, BD; Goldschmidt, RM; Macielag, MJ; Paget, SD; Webb, GC; Wira, E | 1 |
| Fiett, J; Gniadkowski, M; Grzesiowski, P; Hryniewicz, W; Izdebski, R; Sadowy, E | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Hashimoto, A; Lucien, E; Marlor, CW; Nelson, DM; Ou, Y; Pais, GC; Podos, SD; Pucci, MJ; Song, Y; Thanassi, JA; Thoma, CL; Wang, Q; Wiles, JA | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA | 1 |
| Cho, JM; Chong, Y; Kim, CK; Kim, CM; Kim, JM; Lee, K; Ro, S; Yong, D; Yum, JH | 1 |
| Chang, CL; Jeong, J; Jeong, SH; Jung, HJ; Kim, HR; Kim, S; Lee, EY; Lee, JN; Shin, JH | 1 |
| Jansen, WT; Milatovic, D; Verel, A; Verhoef, J | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Dewasse, B; Kosowska-Shick, K; McGhee, P | 1 |
| Clark, NC; Hageman, J; McDonald, LC; McDougal, LK; Patel, JB; Zhu, W | 1 |
| Fritsche, TR; Jones, RN; Sader, HS | 2 |
| Baudry, PJ; DeCorby, M; Hoban, DJ; Johnson, J; Karlowsky, JA; Lagacé-Wiens, P; Laing, N; McCracken, M; Mulvey, MR; Nichol, KA; Tailor, F; Vashisht, R; Walkty, A; Weshnoweski, B; Wierzbowski, A; Zhanel, GG | 1 |
| Danese, P; DeVito, J; Franceschi, F; Lawrence, L; Sutcliffe, J | 1 |
| Laohavaleeson, S; Nicolau, DP; Tessier, PR | 1 |
| Brickner, SJ; Duignan, J; Finegan, S; Girard, D; Huband, MD; Le, PT; Maloney, M; Schafer, J; Stone, GG; Wade, SK; Zaniewski, RP | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Benton, BM; Draghi, DC; Krause, KM; Pillar, C; Sahm, DF; Thornsberry, C | 1 |
| Benton, BM; Debabov, DV; Difuntorum, S; Krause, KM; Renelli, M; Wu, TX | 1 |
| Amsler, KM; Bush, K; Davies, TA; Jacobs, MR; Shang, W | 1 |
| Biek, D; Ge, Y; Sahm, DF; Talbot, GH | 1 |
| Gentry, DR; Gwynn, MN; Holmes, DJ; McCloskey, L; Rittenhouse, SF; Scangarella, N; Shawar, R | 1 |
| Bohnert, JA; Fähnrich, E; Kern, WV; Schuster, S; Wehmeier, C | 1 |
| Bradford, PA; Jones, CH; Mansour, TS; Petersen, PJ; Projan, SJ; Venkatesan, AM | 1 |
| Baldoni, D; Haschke, M; Rajacic, Z; Trampuz, A; Zimmerli, W | 1 |
| Cui, L; Hiramatsu, K; Neoh, HM; Shoji, M | 1 |
| Bell, JM; Biedenbach, DJ; Jones, RN; Sader, HS; Turnidge, JD | 1 |
| Crabb, DM; Duffy, LB; Waites, KB | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Hafkin, B; Hoban, DJ; Kaplan, N; Karlowsky, JA; Zhanel, GG | 1 |
| Chen, H; Chen, M; Liu, Y; Ma, Y; Nichols, WW; Sun, W; Wang, H; Zhang, J; Zhao, C | 1 |
| Han, S; Hwang, JK; Lee, K; Rukayadi, Y; Yong, D | 1 |
| Inagaki, H; Ito, M; Kawakami, K; Matsuhashi, N; Miyauchi, R; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Banevicius, MA; Crandon, JL; Koomanachai, P; Nicolau, DP; Peng, L | 1 |
| Arhin, FF; Draghi, DC; Moeck, G; Parr, TR; Pillar, CM; Sahm, DF | 1 |
| Cai, L; Gilbert, GL; Kong, F; Oftadeh, S; Xiao, M; Xu, X; Zhou, F | 1 |
| Chen, HC; King, CH; Lai, JF; Lauderdale, TL; Shiau, YR | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Brown, SD; Traczewski, MM | 1 |
| Bajaksouzian, S; Biek, D; Critchley, IA; Good, CE; Jacobs, MR; Jones, RN; Sader, HS; Windau, AR | 1 |
| Janechek, MJ; Jones, RN; Mendes, RE; Moet, GJ | 1 |
| Bavari, S; Bowlin, TL; Butler, MM; Moir, DT; Panchal, RG; Peet, NP; Shinabarger, DL; Williams, JD | 1 |
| Bradbury, BJ; Deshpande, M; Hashimoto, A; Kim, HY; Lucien, E; Nelson, DM; Pais, GC; Podos, SD; Pucci, MJ; Thanassi, JA; Wang, Q; Wiles, JA | 1 |
| Achorn, C; Chen, CL; Clark, RB; Deng, Y; Fyfe, C; Grossman, TH; He, M; Hogan, PC; Hunt, DK; O'Brien, WJ; Plamondon, L; Rönn, M; Sutcliffe, JA; Xiao, XY; Zhu, Z | 1 |
| Alm, RA; Barthlow, H; Brassil, P; Breen, J; Ciaccio, P; Comita-Prevoir, J; Cronin, M; Ehmann, DE; Fisher, SL; Geng, B; Godfrey, AA; Goteti, K; McNulty, J; Newman, JV; Reck, F | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bonvin, Y; Briet, S; Denis, A; Desroy, N; Drocourt, E; Durant, L; Escaich, S; Faivre, F; Floquet, S; Genevard, JM; Gerusz, V; LeFralliec, G; Moreau, F; Oliveira, C; Oxoby, M; Peltier, L; Prouvensier, L; Raymond, C; Saccomani, M; Sam-Sambo, V; Soulama-Mouze, C; Vongsouthi, V; Walton, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Alm, R; Basarab, GS; Bist, S; Dangel, PB; Eakin, AE; Garner, CE; Green, O; Hauck, S; Hill, PJ; Hull, K; Illingworth, R; Manchester, JI; Rooney, M; Sherer, BA; Uria-Nickelsen, M; Zhou, F | 1 |
| Basarab, GS; Brassil, P; Doig, P; Galullo, V; Gowravaram, M; Haimes, HB; Kern, G; Kutschke, A; McNulty, J; Schuck, VJ; Stone, G | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Steenbergen, J; Tanaka, SK; Villano, S | 1 |
| Brozovic, A; Dowson, CG; Gazvoda, M; Košmrlj, J; Lloyd, A; Osmak, M; Proud, C; Roper, DI; Vajs, J | 1 |
| Alverson, JB; Decato, D; Hoody, J; Klepacki, D; McGrath, K; Priestley, ND; Stierle, AA; Stierle, DB | 1 |
| Deshmukh, MS; Jain, N | 1 |
| Kalra, S; Khatik, GL; Kumar, GN; Kumar, R; Narang, R; Nayak, SK; Singh, SK; Sudhakar, K | 1 |
| Mabhula, A; Singh, V | 1 |
| Amada, H; Endo, M; Hitaka, K; Kamitani, M; Masuko, A; Mihara, Y; Mima, M; Ohtake, N; Sugiyama, H; Takata, I; Takeuchi, T; Tamura, Y; Tanaka-Yamamoto, N; Ushiyama, F; Wada, R | 1 |
| Akhir, A; Chopra, S; Kaul, G; Meenu, MT; Radhakrishnan, KV; Shukla, M | 1 |
| Trissel, LA; Williams, KY; Xu, QA; Zhang, Y | 1 |
| Georgopoulos, A; Graninger, W; Grisold, A; Mueller-Uri, P; Presterl, E | 1 |
| Ho, PL; Ng, TK; Que, TL; Tse, CW; Yip, EK; Yuen, KY; Yung, RW | 1 |
| Bercion, R; Carricajo, A; Celard, M; Chomarat, M; Croizé, J; Delubac, F; Fèvre, D; Frédénucci, I; Fuhrmann, C; Helfre, M; Lelièvre, H; Letouzey, MN; Mandjee, A; Marthelet, P; Meley, R; Perrier-Gros-Claude, JD; Ros, A; Roure, C; Smati, S; Thierry, J; Tous, J | 1 |
| López, M; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| López, M; Rodriguez Díaz, JC; Royo, G; Ruiz, M | 1 |
| Cirioni, O; D'Amato, G; Del Prete, MS; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Silvestri, C | 1 |
| Akins, RL; Cha, R; Rybak, MJ | 1 |
| García-Tapia, A; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Almela, M; Jurado, A; Marco, F; Mensa, J; Ortega, M; Soriano, A | 1 |
| Anguita-Alonso, P; Jacofsky, DJ; Osmon, DR; Patel, R; Piper, KE; Rouse, MS | 1 |
| Murphy, CK; Osburne, MS; Rothstein, DM | 1 |
| Ariza, J; Cabellos, C; Doménech, A; Garcia, A; Gudiol, F; Murillo, O; Tubau, F | 1 |
| Bohnert, JA; Fähnrich, E; Kern, WV; Schuster, S; Trittler, R | 1 |
| Cantón, E; Colombo Gainza, E; Gil Brusola, A; Gobernado, M; Ortiz Estévez, R; Sahuquillo Arce, JM | 1 |
| Benninger, MS; Brown, NP; Evangelista, AT; Sahm, DF; Thornsberry, C; Yee, YC | 1 |
| Baietto, L; D'Avolio, A; De Rosa, FG; Di Perri, G; Garazzino, S; Patanella, S; Sciandra, M; Siccardi, M | 1 |
| Cervera, C; del Río, A; Fernández-Ruiz, M; Marco, F; Miró, JM; Moreno, A; Pérez, G; Pitart, C | 1 |
| Blair, M; Blair, N; Fiscella, R; George, JM; Pontiggia, L; Rodvold, K; Stokes, J; Ulanski, L | 1 |
| Biek, D; Costello, AJ; Critchley, IA; Diekema, DJ; Doern, GV; Dohrn, CL; Heilmann, KP; Kroeger, JS; Riahi, F; Richter, SS | 1 |
| Ahmed, I; Hasan, R; Inayat, R; Jabeen, K | 1 |
| Helmy, SA | 1 |
| Jeong, BH; Koh, WJ; Kwon, YS | 1 |
| Boyanova, L; Evstatiev, I; Gergova, G; Mitov, I; Yaneva, P | 1 |
| Bourgeois-Nicolaos, N; Cattoir, V; Decousser, JW; Desroches, M; Doucet-Populaire, F; Jehl, F; Lina, G; Potier, J; Vandenesh, F | 1 |
| Nesher, L; Prince, RA; Rolston, KV; Shelburne, SA; Wang, W | 1 |
| Bravo-Molina, A; Hernández-Quero, J; Linares-Palomino, JP; Lozano-Alonso, S; Ros-Díe, E; Vera-Arroyo, B | 1 |
| Bohnert, JA; Handzlik, J; Kaczor, A; Karcz, T; Kern, WV; Kieć-Kononowicz, K; Olejarz, A; Schuster, S | 1 |
| Jones, RN; Mendes, RE; Schuchert, JE | 1 |
| Jiménez Gómez, M; Lindo Ricce, M; P Gisbert, J; Rodriguez-Batllori Arán, B; Santander, C | 1 |
| Jung, JA; Kaisar, N; Parvez, MM; Shin, HJ; Shin, JG | 1 |
| Alfa, M; Head, BM; Meyers, AF; Rubinstein, E; Sitar, DS | 1 |
| Head, BM; Meyers, AF; Rubinstein, E | 1 |
| Bacchi, S; Carlucci, G; Carlucci, M; Cichella, A; Cotellese, R; Di Marco, L; Ferrone, V; Raimondi, P | 1 |
| Duncan, LR; Flamm, RK; Mendes, RE; Pfaller, MA; Sader, HS | 1 |
| Barkan, D; Grosfeld, T; Meir, M | 1 |
| Bar-David, E; Ben-Shmuel, A; Brosh, T; Glinert, I; Kobiler, D; Levy, H; Schlomovitz, J; Sittner, A; Weiss, S | 1 |
| Decousser, JW; Dowzicky, MJ; Fines-Guyon, M; Soussy, CJ; Woerther, PL | 1 |
| Baldin, VP; Caleffi-Ferracioli, KR; Campanerut-Sá, PAZ; Cardoso, RF; de Almeida, AL; Nakamura de Vasconcelos, SS; Santos, NCS; Scodro, RBL; Siqueira, VLD | 1 |
| Ahmad, N; Ahuja, SD; Akkerman, OW; Alffenaar, JC; Anderson, LF; Baghaei, P; Bang, D; Barry, PM; Bastos, ML; Behera, D; Benedetti, A; Bisson, GP; Boeree, MJ; Bonnet, M; Brode, SK; Brust, JCM; Cai, Y; Caumes, E; Cegielski, JP; Centis, R; Chan, ED; Chan, PC; Chang, KC; Charles, M; Cirule, A; D'Ambrosio, L; Dalcolmo, MP; de Vries, G; Dheda, K; Esmail, A; Flood, J; Fox, GJ; Fréchet-Jachym, M; Fregona, G; Gayoso, R; Gegia, M; Gler, MT; Gu, S; Guglielmetti, L; Holtz, TH; Hughes, J; Isaakidis, P; Jarlsberg, L; Kempker, RR; Keshavjee, S; Khan, FA; Kipiani, M; Koenig, SP; Koh, WJ; Kritski, A; Kuksa, L; Kvasnovsky, CL; Kwak, N; Lan, Z; Lange, C; Laniado-Laborín, R; Lee, M; Leimane, V; Leung, CC; Leung, EC; Li, PZ; Lowenthal, P; Maciel, EL; Marks, SM; Mase, S; Mbuagbaw, L; Menzies, D; Migliori, GB; Milanov, V; Miller, AC; Mitnick, CD; Modongo, C; Mohr, E; Monedero, I; Nahid, P; Ndjeka, N; O'Donnell, MR; Padayatchi, N; Palmero, D; Pape, JW; Podewils, LJ; Reynolds, I; Riekstina, V; Robert, J; Rodriguez, M; Schnippel, K; Seaworth, B; Seung, KJ; Shim, TS; Singla, R; Smith, SE; Sotgiu, G; Sukhbaatar, G; Tabarsi, P; Tiberi, S; Trajman, A; Trieu, L; Udwadia, ZF; van der Werf, TS; Veziris, N; Viiklepp, P; Vilbrun, SC; Walsh, K; Westenhouse, J; Yew, WW; Yim, JJ; Zetola, NM; Zignol, M | 1 |
| Bantubani, N; Chotoo, S; Conradie, F; Enwerem, M; Ferreira, H; Hughes, J; Ismail, N; Maartens, G; Master, I; Meintjes, G; Mohr, E; Ndjeka, N; Padanilam, X; Romero, R; Schnippel, K; Singh, N; Te Riele, J; Variava, E | 1 |
| Ahn, H; Ahn, JH; Cho, SN; Hahn, S; Jang, JY; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, CK; Kim, DK; Kim, JS; Kim, SY; Kim, YR; Koh, WJ; Lee, JH; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Shim, TS; Shin, S; Shin, SJ; Song, T; Won, HJ; Yim, JJ | 1 |
| Caleffi-Ferracioli, KR; Cardoso, RF; Costacurta, GF; da Silva, LA; de Almeida, AL; de Pádua, RA; do Prado, SM; Ghiraldi Lopes, LD; Ieque, AL; Leal, DC; Micheletti, DF; Sampiron, EG; Santos, NCS; Scodro, RBL; Siqueira, VL | 1 |
| Chudzik-Rząd, B; Malm, A; Paneth, A; Plech, T; Trotsko, N; Wujec, M | 1 |
| E R, V; Keny, S; Lawande, D; Parrikar, A | 1 |
| Dash, A; Gupta, N; Kodan, P; Ray, Y; Singh, BK; Soneja, M | 1 |
| Draper, HR; Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; van der Laan, LE; Winckler, JL | 1 |
| Goto, K; Itoh, H; Kai, M; Kitano, T; Ohchi, Y; Suzuki, Y; Tanaka, R; Tatsuta, R; Yasuda, N | 2 |
| Chaudhary, S; Garg, V; Maji, S; Singh, V | 1 |
| Chen, YH; Chen, YS; Cheng, SH; Hsueh, PR; Ko, WC; Lee, CM; Lee, WS; Lee, YL; Lin, CN; Lin, CY; Liu, CP; Lu, MC; Lu, PL; Shao, PL; Sheng, WH; Shi, ZY; Tang, HJ; Tsai, YT; Tseng, SH; Wang, FD; Wang, LS; Wu, TS; Yen, MY | 1 |
| Jiang, H; Li, X; Niu, Q; Xing, Z; Xu, J | 1 |
| Kamoshita, F; Karaushi, H; Mitsutake, K; Miyawaki, Y; Seki, M; Watanabe, N | 1 |
| Ahn, JH; Cho, SN; Hahn, S; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, DK; Kim, J; Kim, JS; Kim, K; Kim, S; Kim, SY; Kim, YR; Kwak, N; Lee, JK; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Seok, KH; Shim, TS; Yim, D; Yim, JJ; Yoon, S | 1 |
| An, Q; Lin, R; Wang, C; Wang, D; Yang, Q | 1 |
| Aalhoul, F; Cotton, F; Fage, D | 1 |
8 review(s) available for levofloxacin and linezolid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
Topics: Anti-Bacterial Agents; Bacteria; Dose-Response Relationship, Drug; Drug Discovery; Humans; Microbial Sensitivity Tests; Molecular Conformation; Tetracyclines | 2016 |
Recent advancements in mechanistic studies and structure activity relationship of F
Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium; Proton-Translocating ATPases; Structure-Activity Relationship | 2019 |
Drug-resistance in
Topics: | 2019 |
Tuberculosis: clinical trials and new drug regimens.
Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Alternative pre-approved and novel therapies for the treatment of anthrax.
Topics: Alpha-Globulins; Anthrax; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Bacterial; Antitoxins; Bacillus anthracis; Bacterial Toxins; Daunorubicin; DNA Helicases; Doxorubicin; Drug Discovery; Fluoroquinolones; Humans; Interferon Inducers; Levofloxacin; Linezolid; Moxifloxacin; Ofloxacin; Polyketides; Serine Proteinase Inhibitors; Tilorone; Virulence | 2016 |
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Carbapenems; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Recurrence; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis.
Topics: Antitubercular Agents; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Mycobacterium tuberculosis; Phenotype; Tuberculosis, Multidrug-Resistant | 2023 |
4 trial(s) available for levofloxacin and linezolid
| Article | Year |
|---|---|
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Skin Diseases, Bacterial; Staphylococcus | 2008 |
Aqueous and vitreous penetration of linezolid and levofloxacin after oral administration.
Topics: Acetamides; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Aqueous Humor; Drug Therapy, Combination; Endophthalmitis; Female; Humans; Levofloxacin; Linezolid; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Oxazolidinones; Time Factors; Tissue Distribution; Vitrectomy; Vitreous Body | 2010 |
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Humans; Levofloxacin; Linezolid; Male; Middle Aged; Multicenter Studies as Topic; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Republic of Korea; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in So
Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Pyrazinamide; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2022 |
106 other study(ies) available for levofloxacin and linezolid
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
Synthesis and antibacterial activity of novel 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-4-oxoquinoline-3-carboxylic acids bearing cyclopropane-fused 2-amino-8-azabicyclo[4.3.0]nonan-8-yl substituents at the C-7 position.
Topics: Anti-Infective Agents; Cyclopropanes; DNA Topoisomerase IV; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2004 |
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.
Topics: Acetamides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus; Linezolid; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Staphylococcus; Streptococcus | 2007 |
Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.
Topics: Bacterial Proteins; Cell Lineage; DNA Transposable Elements; Genetic Variation; Poland; Streptococcus pneumoniae; Tetracycline; Tetracycline Resistance | 2007 |
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
Topics: Animals; Anti-Bacterial Agents; Cell Line, Tumor; Drug Resistance, Multiple, Bacterial; Female; Humans; Methicillin Resistance; Mice; Quinolones; Staphylococcus aureus; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2007 |
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles | 2007 |
In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.
Topics: Acetamides; Anti-Infective Agents; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Enzyme Inhibitors; Humans; In Vitro Techniques; Korea; Linezolid; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Pyridines; Staphylococcus; Staphylococcus aureus; Thienopyridines; Thiophenes | 2007 |
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Genes, Bacterial; Hospitals; Humans; Korea; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Ofloxacin; Pneumococcal Infections; Polymerase Chain Reaction; Prevalence; Reserpine; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae | 2007 |
In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Europe; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pyogenes; Vancomycin Resistance; Viridans Streptococci | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
Topics: Acetamides; Anti-Bacterial Agents; Daptomycin; Drug Resistance, Multiple, Bacterial; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Enzyme Inhibitors; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Pyridines; Staphylococcus aureus; Thienopyridines; Thiophenes; Virginiamycin | 2007 |
Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbon-Oxygen Ligases; Conjugation, Genetic; DNA Transposable Elements; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Enterococcus faecalis; Humans; Michigan; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Restriction Mapping; Staphylococcal Infections; Staphylococcus aureus; Vancomycin Resistance | 2008 |
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; United States | 2008 |
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; Canada; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance | 2008 |
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
Topics: Anti-Infective Agents; Bacteria; Community-Acquired Infections; Cross Infection; Enterococcus; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Respiratory System; Staphylococcus; Staphylococcus aureus; Streptococcus; Streptococcus pneumoniae | 2008 |
Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Cross Infection; Disease Models, Animal; Drug Resistance, Bacterial; Female; Humans; Methicillin Resistance; Mice; Mice, Inbred BALB C; Phenotype; Pneumonia, Staphylococcal; Staphylococcus aureus | 2008 |
In vitro antibacterial activity of CE-156811, a novel analog derived from hygromycin A.
Topics: Acetamides; Anti-Bacterial Agents; Cinnamates; Dioxoles; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Hygromycin B; In Vitro Techniques; Linezolid; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Prospective Studies; Staphylococcus aureus; Streptococcus; Streptococcus pneumoniae; United States | 2008 |
In vitro activity of telavancin against resistant gram-positive bacteria.
Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; In Vitro Techniques; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus; Streptococcus | 2008 |
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; United States | 2008 |
Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.
Topics: Anti-Bacterial Agents; ATP-Binding Cassette Transporters; Bacterial Proteins; Bridged Bicyclo Compounds, Heterocyclic; Diterpenes; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Pleuromutilins; Polycyclic Compounds; Sequence Analysis, DNA; Staphylococcus aureus | 2008 |
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Macrolides; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutagenesis, Site-Directed; Sequence Homology, Amino Acid | 2009 |
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactamase Inhibitors; Drug Combinations; Enzyme Inhibitors; Humans; Lactams; Microbial Sensitivity Tests; Piperacillin | 2009 |
Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Therapy, Combination; Foreign-Body Reaction; Guinea Pigs; Injections, Intraperitoneal; Linezolid; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Animal; Oxazolidinones; Plankton; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Time Factors | 2009 |
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Chromosome Walking; DNA-Binding Proteins; Genetic Engineering; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Point Mutation; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2009 |
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
Topics: Anti-Bacterial Agents; Asia; Drug Resistance, Bacterial; Europe; Gram-Positive Bacteria; Humans; Latin America; Microbial Sensitivity Tests; North America; Pacific Ocean; Quality Control; Teicoplanin; Vancomycin | 2009 |
Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; Ketolides; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma fermentans; Mycoplasma genitalium; Mycoplasma Infections; Mycoplasma pneumoniae; Ureaplasma; Ureaplasma Infections | 2009 |
Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.
Topics: Anti-Bacterial Agents; Enterococcus faecalis; Europe; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Hospitalization; Humans; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrimidines; Staphylococcus aureus; Streptococcus; United States | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
Topics: Anti-Bacterial Agents; Benzofurans; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Enterobacteriaceae; Enterococcus; Microbial Sensitivity Tests; Moraxella catarrhalis; Pyrones; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae | 2009 |
Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
Topics: Anti-Bacterial Agents; China; Cities; Drug Resistance, Multiple, Bacterial; Humans; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Vancomycin; Vancomycin Resistance | 2009 |
In vitro activities of panduratin A against clinical Staphylococcus strains.
Topics: Anti-Bacterial Agents; Chalcones; Humans; Microbial Sensitivity Tests; Molecular Structure; Staphylococcus; Zingiberaceae | 2009 |
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2009 |
Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
Topics: Animals; Anti-Bacterial Agents; Female; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred BALB C; Minocycline; Pneumonia; Staphylococcal Infections; Tigecycline | 2009 |
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus faecium; Glycopeptides; Gram-Positive Bacteria; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus | 2009 |
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; New South Wales; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae | 2010 |
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones; Taiwan | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.
Topics: Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Enterococcaceae; Gram-Positive Bacteria; History, Medieval; In Vitro Techniques; Indicator Dilution Techniques; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Microbiological Techniques; Organophosphates; Oxazoles; Oxazolidinones; Quality Control; Streptococcus; Tetrazoles | 2010 |
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Communicable Diseases, Emerging; Drug Resistance, Multiple, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; United States | 2010 |
In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Daptomycin; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Linezolid; Lipoglycopeptides; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Staphylococcal Infections; Staphylococcus aureus; Vancomycin; Virginiamycin | 2010 |
Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
Topics: Anti-Bacterial Agents; Gram-Negative Aerobic Bacteria; Gram-Positive Bacteria; Indoles; Microbial Sensitivity Tests | 2010 |
Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Anti-Bacterial Agents; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Escherichia coli; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrrolidines; Quinolones; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2011 |
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Biological Availability; Cyclophosphamide; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Lung; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neutropenia; Rats; Rats, Sprague-Dawley; Respiratory Tract Infections; Ribosomes; Sepsis; Stereoisomerism; Structure-Activity Relationship; Tetracycline Resistance; Tetracyclines | 2012 |
Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Biological Availability; Dioxanes; DNA Topoisomerase IV; Dogs; Drug Resistance, Bacterial; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Piperidines; Quinolones; Staphylococcal Infections; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
Topics: Animals; Anti-Infective Agents, Local; Benzamides; Cells, Cultured; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Phenyl Ethers; Rats; Structure-Activity Relationship; Triclosan | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099).
Topics: Adenosine Triphosphatases; Amides; Animals; Anti-Bacterial Agents; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, Knockout; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrroles; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2014 |
Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.
Topics: Animals; Anti-Bacterial Agents; Barbiturates; Female; Fluoroquinolones; Heterocyclic Compounds, 4 or More Rings; Humans; Inhibitory Concentration 50; Isoxazoles; Male; Mice; Pyridones; Rats, Wistar; Spiro Compounds; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
Topics: Anti-Bacterial Agents; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mycobacterium smegmatis; Triazenes | 2017 |
The Berkeleylactones, Antibiotic Macrolides from Fungal Coculture.
Topics: Anti-Bacterial Agents; Coculture Techniques; Macrolides; Microbial Sensitivity Tests; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Penicillium; Streptococcus pneumoniae; Streptococcus pyogenes | 2017 |
Design, Synthesis, and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure.
Topics: | 2017 |
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
Topics: Anti-Bacterial Agents; Cell Survival; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Hep G2 Cells; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Quinolines; Streptococcus pneumoniae; Structure-Activity Relationship; Topoisomerase II Inhibitors; Transcriptional Regulator ERG; Vancomycin-Resistant Enterococci | 2020 |
Developing the Natural Prenylflavone Artocarpin from
Topics: Animals; Anti-Bacterial Agents; Artocarpus; Biofilms; Flavonoids; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus | 2022 |
Compatibility and stability of linezolid injection admixed with three quinolone antibiotics.
Topics: Acetamides; Anti-Infective Agents; Ciprofloxacin; Drug Stability; Levofloxacin; Linezolid; Ofloxacin; Oxazolidinones | 2000 |
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Base Sequence; Ciprofloxacin; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Oxazolidinones; Polymerase Chain Reaction; Quinolines; Sensitivity and Specificity; Staphylococcus aureus; Teicoplanin; Vancomycin | 2001 |
Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in Hong Kong.
Topics: Acetamides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus; Gram-Positive Bacterial Infections; Hong Kong; Humans; Levofloxacin; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Oxazolidinones; Staphylococcus aureus; Streptococcus pneumoniae; Vancomycin Resistance | 2001 |
Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Ketolides; Lactams; Levofloxacin; Linezolid; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Oxazolidinones; Penicillin G; Pristinamycin; Quinolines; Streptococcus pneumoniae; Virginiamycin | 2002 |
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Topics: Acetamides; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Tuberculosis | 2002 |
In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Ofloxacin; Oxazolidinones; Quinolines; Spain | 2003 |
Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection caused by Staphylococcus epidermidis with intermediate resistance to glycopeptides.
Topics: Acetamides; Animals; Antibiotic Prophylaxis; Drug Resistance, Bacterial; Drug Therapy, Combination; Glycopeptides; Graft Rejection; Levofloxacin; Linezolid; Male; Microbial Sensitivity Tests; Ofloxacin; Oxazolidinones; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus epidermidis; Vancomycin | 2003 |
Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Topics: Acetamides; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Ofloxacin; Oxazolidinones; Streptococcus pneumoniae; Vancomycin | 2003 |
Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Rifampin; Structure-Activity Relationship; Time Factors | 2004 |
[In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Clindamycin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Oxazolidinones; Quinolines; Rifampin; Staphylococcus aureus; Staphylococcus epidermidis | 2005 |
Comparative study of antimicrobial release kinetics from polymethylmethacrylate.
Topics: Acetamides; Anti-Bacterial Agents; Area Under Curve; Cefazolin; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Ofloxacin; Oxazolidinones; Polymethyl Methacrylate; Rifampin | 2006 |
Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro.
Topics: Acetamides; Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Mupirocin; Ofloxacin; Oxazolidinones; Rifamycins; Staphylococcus aureus | 2006 |
Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cloxacillin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Foreign-Body Reaction; Humans; Levofloxacin; Linezolid; Male; Methicillin; Microbial Sensitivity Tests; Ofloxacin; Oxazolidinones; Rats; Rats, Wistar; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2006 |
Altered spectrum of multidrug resistance associated with a single point mutation in the Escherichia coli RND-type MDR efflux pump YhiV (MdtF).
Topics: Acetamides; Alleles; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B; DNA, Bacterial; DNA, Complementary; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Levofloxacin; Linezolid; Membrane Transport Proteins; Microbial Sensitivity Tests; Models, Molecular; Ofloxacin; Oxazolidinones; Phenotype; Phenylalanine; Point Mutation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Bacterial | 2007 |
In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Doxycycline; Drug Therapy, Combination; Enzyme Inhibitors; Fosfomycin; Humans; In Vitro Techniques; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Ofloxacin; Oxazolidinones; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2006 |
Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001-2005).
Topics: Acetamides; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactam Resistance; Cefuroxime; Cephalosporin Resistance; Clindamycin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Erythromycin; Humans; Levofloxacin; Linezolid; Ofloxacin; Oxazolidinones; Paranasal Sinuses; Penicillin Resistance; Population Surveillance; Streptococcus pneumoniae; Trimethoprim Resistance; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 2007 |
Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV.
Topics: Acetamides; Anti-Bacterial Agents; Antibiotics, Antitubercular; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Moxifloxacin; Ofloxacin; Oxazolidinones; Quality Control; Quinolines; Reference Standards; Reproducibility of Results; Rifampin; Solutions; Solvents; Spectrophotometry, Ultraviolet | 2009 |
Community-acquired methicillin-resistant Staphylococcus aureus meningitis complicated by cerebral infarction. Role of antibiotic combination of linezolid plus levofloxacin.
Topics: Acetamides; Adult; Anti-Bacterial Agents; Cerebral Infarction; Community-Acquired Infections; Drug Therapy, Combination; Humans; Levofloxacin; Linezolid; Male; Meningitis, Bacterial; Methicillin-Resistant Staphylococcus aureus; Ofloxacin; Oxazolidinones; Staphylococcal Infections | 2010 |
Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.
Topics: Acetamides; Bacterial Toxins; Ceftaroline; Cephalosporins; Clindamycin; Daptomycin; Electrophoresis, Gel, Pulsed-Field; Erythromycin; Exotoxins; Leukocidins; Levofloxacin; Linezolid; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mupirocin; Ofloxacin; Oxacillin; Oxazolidinones; Polymerase Chain Reaction; Staphylococcus aureus; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination; United States; Vancomycin | 2011 |
Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.
Topics: Acetamides; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Pakistan; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers.
Topics: Acetamides; Adult; Anti-Infective Agents; Aza Compounds; Chromatography, High Pressure Liquid; Drug Monitoring; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Limit of Detection; Linezolid; Male; Moxifloxacin; Norfloxacin; Oxazolidinones; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Tinidazole; Young Adult | 2013 |
Linezolid susceptibility in Helicobacter pylori, including strains with multidrug resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Linezolid; Metronidazole; Microbial Sensitivity Tests; Tetracycline | 2015 |
Susceptibility trends including emergence of linezolid resistance among coagulase-negative staphylococci and meticillin-resistant Staphylococcus aureus from invasive infections.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Coagulase; Drug Resistance, Multiple, Bacterial; France; Fusidic Acid; Gentamicins; Hospitals; Humans; Levofloxacin; Linezolid; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Prospective Studies; Rifampin; RNA, Ribosomal, 23S; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Staphylococcal Infections; Staphylococcus epidermidis | 2015 |
In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.
Topics: Anti-Bacterial Agents; Daptomycin; Gram-Positive Bacteria; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Neoplasms; Teicoplanin; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin | 2016 |
[Evaluation of the tissue diffusion capacity of antibiotics in lower limb ischaemia].
Topics: Aged; Anti-Bacterial Agents; Ceftazidime; Chromatography, High Pressure Liquid; Clindamycin; Female; Humans; Ischemia; Levofloxacin; Linezolid; Lower Extremity; Male; Meropenem; Microbial Sensitivity Tests; Prospective Studies; Skin; Thienamycins; Vancomycin | 2016 |
Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Biological Assay; Biological Transport; Cell Membrane; Cephalosporins; Clarithromycin; Drug Synergism; Escherichia coli; Escherichia coli Proteins; Fluorescent Dyes; Gene Expression; Imidazoles; Indicators and Reagents; Kinetics; Levofloxacin; Linezolid; Membrane Proteins; Membrane Transport Proteins; Microbial Sensitivity Tests; Oxacillin; Piperazines; Protein Kinases; Repressor Proteins; Rifampin | 2016 |
Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).
Topics: Anti-Bacterial Agents; Ceftriaxone; Cephalosporins; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Penicillins; Streptococcus pneumoniae; Teicoplanin; Vancomycin | 2016 |
Non-responsive coeliac disease: Coeliac crisis vs. refractory coeliac disease with response to corticosteroids.
Topics: Autoantibodies; Autoantigens; Bipolar Disorder; Celiac Disease; Diarrhea; Diet, Gluten-Free; Dissociative Disorders; Drug Therapy, Combination; Female; GTP-Binding Proteins; Humans; Immunoglobulin A; Levofloxacin; Linezolid; Methylprednisolone; Middle Aged; Pneumonia; Protein Glutamine gamma Glutamyltransferase 2; Protein-Energy Malnutrition; Respiratory Insufficiency; Transglutaminases | 2017 |
Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family.
Topics: 1-Methyl-4-phenylpyridinium; Aminosalicylic Acid; Animals; Antitubercular Agents; Ciprofloxacin; HEK293 Cells; Humans; Inhibitory Concentration 50; Ion Transport; Kinetics; Levofloxacin; Linezolid; Metformin; Octamer Transcription Factor-1; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pyrazinamide; Rifabutin; Rifampin; Zidovudine | 2016 |
In vitro evaluation of the effect of linezolid and levofloxacin on Bacillus anthracis toxin production, spore formation and cell growth.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Bacillus anthracis; Bacterial Toxins; Drug Synergism; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Microbial Viability; Spores, Bacterial | 2017 |
Meropenem, levofloxacin and linezolid in human plasma of critical care patients: A fast semi-automated micro-extraction by packed sorbent UHPLC-PDA method for their simultaneous determination.
Topics: Automation; Chromatography, High Pressure Liquid; Critical Care; Humans; Levofloxacin; Limit of Detection; Linezolid; Meropenem; Solid Phase Microextraction; Thienamycins | 2017 |
Topics: Academic Medical Centers; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Tigecycline; United States | 2018 |
Establishment and Validation of Galleria mellonella as a Novel Model Organism To Study Mycobacterium abscessus Infection, Pathogenesis, and Treatment.
Topics: Amikacin; Animals; Larva; Levofloxacin; Linezolid; Meropenem; Moths; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Tigecycline | 2018 |
Treating Anthrax-Induced Meningitis in Rabbits.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antitoxins; Bacillus anthracis; Central Nervous System; Ciprofloxacin; Clindamycin; Dexamethasone; Disease Models, Animal; Drug Combinations; Imipenem; Levofloxacin; Linezolid; Meningitis, Bacterial; Meropenem; Rabbits; Treatment Failure | 2018 |
The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
Topics: Acinetobacter baumannii; Amikacin; Drug Resistance, Multiple, Bacterial; Enterococcus; Escherichia coli; France; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Klebsiella pneumoniae; Levofloxacin; Linezolid; Meropenem; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Streptococcus pneumoniae; Tigecycline; Vancomycin | 2018 |
Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Isoniazid; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin | 2018 |
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Resistance, Bacterial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; HIV Infections; Humans; Levofloxacin; Linezolid; Male; Middle Aged; Poisson Distribution; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2018 |
Determination of minimum bactericidal concentration, in single or combination drugs, against
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Isoniazid; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin; Tuberculosis | 2020 |
Synergistic Effects of Thiosemicarbazides with Clinical Drugs against
Topics: Amoxicillin; Anti-Bacterial Agents; Cell Line; Cell Survival; DNA Gyrase; DNA Topoisomerase IV; Drug Combinations; Drug Synergism; Fibroblasts; Gene Expression; Gentamicins; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Semicarbazides; Staphylococcus aureus; Structure-Activity Relationship; Vancomycin | 2020 |
Gitelman-like syndrome: A rare complication of using aminoglycosides in tuberculosis - A case report.
Topics: Alkalosis; Antitubercular Agents; Capreomycin; Clofazimine; Cycloserine; Deprescriptions; Ethionamide; Gitelman Syndrome; Humans; Hypocalcemia; Hypokalemia; Levofloxacin; Linezolid; Male; Middle Aged; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Water-Electrolyte Imbalance | 2020 |
Choosing the therapy for neurological infection with rapidly growing mycobacteria.
Topics: Administration, Intravenous; Adolescent; Amikacin; Central Nervous System Bacterial Infections; Clinical Decision-Making; Female; Humans; Imipenem; Levofloxacin; Linezolid; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Ventriculoperitoneal Shunt | 2020 |
Acceptability of levofloxacin, moxifloxacin and linezolid among children and adolescents treated for TB.
Topics: Adolescent; Anti-Bacterial Agents; Aza Compounds; Child; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Tuberculosis | 2020 |
Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Azoles; Carbapenems; Chromatography, High Pressure Liquid; Ciprofloxacin; Daptomycin; Doripenem; Drug Monitoring; Female; Fluconazole; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Linezolid; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Oxazines; Oxazolidinones; Quinolones; Tandem Mass Spectrometry; Tetrazoles; Voriconazole | 2021 |
Isolated multidrug-resistant tubercular tenosynovitis of the flexor tendon of the little finger.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antitubercular Agents; Clofazimine; Cycloserine; Diagnosis, Differential; Drug Resistance, Multiple; Ethambutol; Female; Fingers; Humans; Levofloxacin; Linezolid; Magnetic Resonance Imaging; Tendons; Tenosynovitis; Tuberculosis; Young Adult | 2021 |
Nationwide surveillance of antimicrobial resistance in invasive isolates of Streptococcus pneumoniae in Taiwan from 2017 to 2019.
Topics: Aged; Anti-Bacterial Agents; Ceftriaxone; Doripenem; Drug Resistance, Bacterial; Ertapenem; Humans; Levofloxacin; Linezolid; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Penicillins; Pneumococcal Infections; Streptococcus pneumoniae; Taiwan; Vancomycin | 2022 |
Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant
Topics: Anti-Bacterial Agents; Antitubercular Agents; Ethambutol; Humans; Levofloxacin; Linezolid; Mycobacterium tuberculosis; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Prothionamide; Pyrazinamide; Reactive Oxygen Species; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |
A Mycobacterium tuberculosis-Infected Patient Who Could Not Tolerate Oral Intake Successfully Treated Using an Intravenous Tedizolid-Containing Regimen.
Topics: Aged; Anti-Bacterial Agents; Antitubercular Agents; Cutaneous Fistula; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Male; Meropenem; Micafungin; Mycobacterium tuberculosis; Oxazolidinones; Pyrazinamide; Rifampin; Streptomycin; Teicoplanin; Tetrazoles; Tuberculosis | 2022 |
UHPLC-MS/MS method for simultaneous quantification of doripenem, meropenem, ciprofloxacin, levofloxacin, pazufloxacin, linezolid, and tedizolid in filtrate during continuous renal replacement therapy.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Continuous Renal Replacement Therapy; Doripenem; Humans; Levofloxacin; Linezolid; Meropenem; Tandem Mass Spectrometry | 2023 |
Protein binding investigation of first-line and second-line antituberculosis drugs.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin; Protein Binding; Pyrazinamide; Rifampin; Tuberculosis | 2023 |